Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.

By C. Eyler, Jeremy N. Rich. Journal of Clinical Oncology, 2008

747 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/15f3d28d55466434606c0379035b8a4919024b7c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. (2011, positive): “Such studies are of particular importance because of the observed resistance of cancer stem-like cells to chemoand radiation therapies (Bao et al., 2006; Dean et al., 2005; Diehn and Clarke, 2006; Eyler and Rich, 2008; Li et al., 2008; Woodward et al., 2007).”
Combination therapy in combating cancer (2017, background): “An additional advantage of combination therapy is that multiple drugs can target the heterogeneous nature of tumours, correspondingly increasing the chance of killing all cancer cells, including the cancer stem cell population that is known to contribute to drug resistance and cancer recurrence afte”
Identification of selective inhibitors of cancer stem cells by high-throughput screening (2009, background): “CSCs are resistant to many current cancer treatments, including chemo- and radiation therapy (Bao et al., 2006; Dean et al., 2005; Diehn et al., 2009; Diehn and Clarke, 2006; Eyler and Rich, 2008; Li et al., 2008; Woodward et al., 2007).”
A chromatin-mediated reversible drug tolerant state in cancer cell subpopulations (2010, background): “Emerging studies of CSCs have clearly revealed their reduced sensitivity to a variety of toxic exposures (Eyler and Rich, 2008), and recent studies have demonstrated that exposure of mouse tumors to certain chemotherapy drugs can cause tumor regression yielding a population of drug-refractory cells ”